Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs.
Neuroendocrine abnormality of the hypothalamic-pituitary-adrenal axis was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs as a model of Parkinson's disease. Blood samples were collected every 4 h for 3-4 days before MPTP treatment, around 2 and 4 weeks after the treatment of MPTP (2.5 mg/kg). Adrenocorticotrophin (ACTH) and cortisol concentrations in plasma were determined by radioimmunoassay. The concentrations of plasma ACTH and cortisol increased by 40% and 60% after MPTP treatment, respectively. Circadian rhythms of neither plasma ACTH nor cortisol concentrations were observed in both MPTP-treated and control dogs. This high hypothalamic-pituitary-adrenal function in MPTP-treated dogs suggests that MPTP may influence the activity of the hypothalamic neurons of the dog.
Mizobuchi
M
M
Department of Neuropsychiatry, Ehime University School of Medicine, Japan.
Hineno
T
T
Kakimoto
Y
Y
Hiratani
K
K
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000097:blood*; D000818:Animals; D002940:Circadian Rhythm / Q000187:drug effects; D004285:Dogs; D015259:Dopamine Agents / Q000494:pharmacology*; D006854:Hydrocortisone / Q000097:blood*; D007031:Hypothalamus / Q000166:cytology / Q000502:physiology; D008297:Male; D009994:Osmolar Concentration; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000378:metabolism; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism
D015259:Dopamine Agents; C048977:1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine; D000324:Adrenocorticotropic Hormone; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D006854:Hydrocortisone